Advertisement

Journal of Neural Transmission

, Volume 59, Issue 4, pp 257–264 | Cite as

3H-imipramine and3H-cyano-imipramine binding in rat brain tissue: Effect of long-term antidepressant administration

  • C. Gentsch
  • M. Lichtsteiner
  • H. Feer
Original Papers

Summary

3H-imipramine and3H-cyano-imipramine binding was determined in brain homogenates of rats which had been treated for 21 days with imipramine or desimipramine. When compared to control animals, long-term administration of these antidepressants did not induce any alteration in the maximal number of3H-imipramine or3H-cyano-imipramine binding sites. However, a transient increase in the apparent dissociation constant was observed. Such findings are discussed in respect to previous studies, which have been highly contraversial.

Keywords

Public Health Binding Site Brain Tissue Dissociation Constant Imipramine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abel M. S., Meyerson, L. R., Clody, D. E., Wennogle, L. P.: Chronic electroconvulsive shock differentially affects brain and platelet3H-imipramine recognition sites. Abstract 210.2, 13th Annual Meeting of the American Society for Neurosciences, Boston (1983).Google Scholar
  2. Arbilla, S., Briley, M., Cathala, F., Langer, S. Z., Porin, C., Raisman, R.: Parallel changes in3H-imipramine binding sites in cat brain and platelets following chronic treatment with imipramine. Br. J. Pharmacol.72, 154p (1980).Google Scholar
  3. Asarch, K. B., Shih, J. C., Kukcar, A.: Decreased3H-imipramine binding in depressed males and females. Commun. in Psychopharmacol.4, 425–432 (1980).Google Scholar
  4. Banerjee, S. P., Kung, L. S., Riggi, S. J., Chanda, S. K.: Development of betaadrenergic receptor subsensitivity by antidepressants. Nature268, 455–456 (1977).PubMedGoogle Scholar
  5. Berrettini, W. H., Nurnberger, J. I., Post, R. M., Gershon, E. S.: Platelet3H-imipramine binding in euthymic bipolar patients. Psychiatry Res.7, 215–219 (1982).PubMedGoogle Scholar
  6. Borbe, H., Zube, I.: The detection of specific3H-imipramine binding sites in bovine retina. Brain Res.264, 178–180 (1983).PubMedGoogle Scholar
  7. Briley, M. S., Raisman, R., Langer, S. Z.: Human platelets possess high affinity binding sites for3H-imipramine. Eur. J. Pharmacol.58, 347–348 (1979).PubMedGoogle Scholar
  8. Briley, M. S., Fillion, G., Beaudoin, D., Fillion, M., Langer, S. Z.:3H-imipramine binding in neuronal and glial fractions of horse striatum. Eur. J. Pharmacol.64, 191–194 (1980).PubMedGoogle Scholar
  9. Briley, M. S., Langer, S. Z., Raisman, R., Sechter, D., Zarifian, E.: Tritiated imipramine binding sites are decreased in platelets of untreated depressed patients. Science209, 303–305 (1980).PubMedGoogle Scholar
  10. Briley, M. S., Raisman, R., Arbilla, S., Casadamont, M., Langer, S. Z.: Concomitant decrease in3H-imipramine binding in cat brain and platelets after chronic treatment with imipramine. Eur. J. Pharmacol.81, 309–314 (1982).PubMedGoogle Scholar
  11. Brunello, N., Chuang, D. M., Costa, E.: Different synaptic localization of mianserin and imipramine binding sites. Science215, 1112–1115 (1982).PubMedGoogle Scholar
  12. Burkard, W. P.: Specific binding sites in rat brain for a new and potent inhibitor of 5-hydroxytryptamine uptake: Ro 11-2465. Eur. J. Pharmacol.61, 409–410 (1980).PubMedGoogle Scholar
  13. Driscoll, P., Bättig, K.: Behavioral and physiological correlates of psychogenetic selection (RHA/Verh vs RLA/Verh rats). In: L'animal de laboratoire au service de l'homme. Collect. Fond. Mérieux, Lyon, 1979.Google Scholar
  14. Dumbrille-Ross, A., Tang, S. W.: Binding of3H-Ro 11-2465. Possible identification of a subclass of3H-imipramine binding sites. Molec. Pharmacol.23, 607–613 (1983).Google Scholar
  15. Engel, G., Hoyer, D., Berthold, R., Wagner, H.: (+)(125Iodo)cyanopindolol, a new ligand for beta-adrenoceptors: Identification and quantification of subclasses of beta-adrenoceptors in guinea pig. Naunyn-Schmiedeberg's Arch. Pharmacol.317, 277–285 (1981).Google Scholar
  16. Friedl, W., Propping, P., Weck, B.:3H-imipramine binding in platelets: influence of varying proportions of intact platelets in membrane preparations on binding. Psychopharmacology80, 96–99 (1983).PubMedGoogle Scholar
  17. Kinnier, W. J., Chuang, D., Costa, E.: Down regulation of dihydroalprenolol and imipramine binding sites in brain of rats repeatedly treated with imipramine. Eur. J. Pharmacol.67, 289–294 (1980).PubMedGoogle Scholar
  18. Langer, S. Z., Javoy-Agid, F., Raisman, R., Briley, M., Agid, Y.: Distribution of specific high-affinity binding sites for3H-imipramine in human brain. J. Neurochem.37, 267–271 (1981).PubMedGoogle Scholar
  19. Langer, S. Z., Zarifian, E., Briley, M., Raisman, R., Sechter, D.: High affinity H-imipramine binding: A new biological marker in depression. Pharmacopsychiatria15, 4–10 (1982).PubMedGoogle Scholar
  20. Lee, C., Javitch, J. A., Snyder, S. H.: Recognition sites for norepinephrine uptake: regulation by neurotransmitter. Science220, 626–629 (1983).PubMedGoogle Scholar
  21. Luine, V. N., Frankfurt, M., Rainbow, T. C., Biegon, A., Azmitia, E.: Intrahypothalamic 5, 7-dihydroxytryptamine facilitates feminine sexual behavior and decreases3H-imipramine binding and 5-HT uptake. Brain Res.264, 344–348 (1983).PubMedGoogle Scholar
  22. Mellerup, E. T., Plenge, P., Rosenberg, R.:3H-imipramine binding sites in platelets from psychiatric patients. Psychiatry Res.7, 221–227 (1982).PubMedGoogle Scholar
  23. Mogilnicka, E., Arbilla, S., Depoortere, H., Langer, S. Z.: Rapid eye movement sleep deprivation decreases the density of3H-dihydroalprenolol and3H-imipramine binding sites in the rat cerebral cortex. Eur. J. Pharmacol.65, 289–292 (1980).PubMedGoogle Scholar
  24. Paul, S. M., Rehavi, M., Skolnick, P., Ballenger, C., Goodwin, K.: Depressed patients have decreased binding of tritiated imipramine to platelet serotonin “transporter”. Arch. Gen. Psychiatry38, 1315–1317 (1981).PubMedGoogle Scholar
  25. Perry, E. K., Marshall, E. F., Blessed, G., Tomlinson, B. E., Perry, R. H.: Decreased imipramine binding in the brains of patients with depressive illness. Brit. J. Psychiatry142, 188–192 (1983).Google Scholar
  26. Plenge, P., Mellerup, E. T.:3H-imipramine high-affinity binding sites in rat brain. Effects of imipramine and lithium. Psychopharmacology77, 94–97 (1982).PubMedGoogle Scholar
  27. Racagni, G., Mocchetti, I., Calderini, G., Battistella, A., Brunello, N.: Temporal sequence of changes in central noradrenergic system of rat after prolonged antidepressant treatment: receptor desensitization and neurotransmitter interactions. Neuropharmacology22, 415–424 (1983).PubMedGoogle Scholar
  28. Raisman, R., Briley, M. S., Langer, S. Z.: Specific tricyclic antidepressant binding sites in rat brain characterized by high-affinity3H-imipramine binding. Eur. J. Pharmacol.61, 373–380 (1980).PubMedGoogle Scholar
  29. Schaffner, W., Weissmann, C.: A rapid, sensitive and specific method for the determination of protein in dilute solutions. Analytical Biochemistry56, 502–514 (1973).PubMedGoogle Scholar
  30. Wan, D., Peck, E. J., Ho, B. T., Schoolar, J. C.: The residual effect of chronic neuroleptic treatment on the neuroleptic binding assay in rats. Life Sci.32, 1255–1262 (1983).PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1984

Authors and Affiliations

  • C. Gentsch
    • 1
  • M. Lichtsteiner
    • 1
  • H. Feer
    • 1
  1. 1.Biochemical LaboratoryPsychiatric University Clinic BasleSwitzerland

Personalised recommendations